BCMA (B-cell maturation antigen; CD269; TNFRSF17) is selectively over-expressed during the malignant transformation of plasma cells, making it an ideal target for the treatment of multiple myeloma [24]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.